These kinds of patients should be managed through a review of dopaminergic drugs, avoiding dopamine agonists and Catechol-O-methyltransferase (COMT) inhibitors, dealing with cognitive impairment, and using more easily atypical antipsychotics [155,158,161]. The gene discussed is COMT; the disease is Cognitive impairment.